FDA Approves First Aldosterone Synthase Inhibitor BAXFENDY to Tackle Resistant Hypertension
AstraZeneca's BAXFENDY cuts systolic blood pressure by nearly 10 mmHg beyond placebo in adults whose BP wasn't controlled by other drugs.
Summary
The FDA has approved BAXFENDY (baxdrostat), a first-of-its-kind drug for adults with high blood pressure that isn't controlled by existing medications. Made by AstraZeneca, it works by blocking aldosterone synthase, an enzyme that drives blood pressure up. In a phase 3 trial of nearly 800 patients, the 2 mg dose reduced systolic blood pressure by 15.7 mmHg overall and 9.8 mmHg more than placebo after 12 weeks. It's taken once daily alongside other blood pressure medications. Side effects include elevated potassium, low sodium, dizziness, and low blood pressure. The drug represents a new mechanism for managing resistant hypertension, a condition linked to higher risks of heart attack, stroke, and kidney disease — all key threats to healthy longevity.
Detailed Summary
High blood pressure that doesn't respond to standard treatments is one of the most stubborn cardiovascular risk factors in medicine. It raises the likelihood of stroke, heart failure, kidney damage, and early death — making any new treatment option genuinely significant for longevity-focused individuals and their clinicians.
Baxdrostat, branded BAXFENDY, is the first approved aldosterone synthase inhibitor, a novel drug class that targets the enzyme responsible for producing aldosterone, a hormone that raises blood pressure by causing the kidneys to retain sodium and water. By blocking this enzyme directly, the drug addresses a root hormonal driver of hypertension rather than simply managing symptoms downstream.
The FDA approval was based on the BaxHTN phase 3 trial involving 796 adults with uncontrolled hypertension. At the 2 mg dose, patients experienced a 15.7 mmHg reduction in seated systolic blood pressure, with a placebo-adjusted reduction of 9.8 mmHg at 12 weeks — a clinically meaningful improvement. The 1 mg dose also showed directional benefit and is recommended for patients at higher risk of electrolyte imbalances.
Side effects are real and worth noting. Hyperkalemia (high potassium) occurred in 6.6% and 10.2% of patients on the 1 mg and 2 mg doses respectively. Low sodium, dizziness, hypotension, and muscle spasms were also reported. These risks mean the drug requires monitoring and isn't appropriate for everyone with elevated blood pressure.
AstraZeneca acquired BAXFENDY through its 2023 purchase of CinCor Pharma and is exploring further applications in cardiorenal disease. For people with treatment-resistant hypertension — a population at elevated risk of accelerated cardiovascular aging — this approval opens a meaningful new therapeutic avenue that addresses a hormone-driven mechanism previously untargetable.
Key Findings
- BAXFENDY reduced systolic BP by 9.8 mmHg more than placebo in adults with uncontrolled hypertension at 12 weeks.
- First-in-class aldosterone synthase inhibitor targets a hormonal root cause of high blood pressure, not just symptoms.
- Approved as add-on therapy for adults inadequately controlled on existing antihypertensive medications.
- Hyperkalemia occurred in up to 10.2% of patients on the 2 mg dose — electrolyte monitoring is essential.
- AstraZeneca is pursuing additional studies in related cardiorenal conditions, expanding potential future applications.
Methodology
This is a news report summarizing an FDA drug approval and associated phase 3 clinical trial data. The source, Longevity.Technology, is a credible health and longevity news outlet. Evidence is based on a phase 3 randomized controlled trial (BaxHTN, n=796), which represents a high standard of clinical evidence.
Study Limitations
This article is a news summary and does not provide full trial data, long-term outcomes, or cardiovascular event endpoints. Electrolyte side effects and patient selection criteria warrant review of the full prescribing label. Cost, availability, and real-world effectiveness data are not yet available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.